Biohaven Ltd
BHVN
View Detailed Chart
10.720USD
+0.220+2.10%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.13BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+2.10%
5 Days
-1.38%
1 Month
+10.74%
6 Months
-27.42%
Year to Date
-71.30%
1 Year
-70.01%
View Detailed Chart
TradingKey Stock Score of Biohaven Ltd
Currency: USD Updated: 2025-10-27Key Insights
Its valuation is considered fairly valued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at max_target_price.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Biohaven Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
18
analysts
Buy
Current Rating
19.563
Target Price
+85.60%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Biohaven Ltd Highlights
StrengthsRisks
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Fairly Valued
The company’s latest PE is -2.33, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 87.60M shares, decreasing 13.13% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 429.00 shares of this stock.
Biohaven Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Biohaven Ltd Info
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
Ticker SymbolBHVN
CompanyBiohaven Ltd
CEOCoric (Vlad)
Websitehttps://www.biohaven.com/
FAQs
What is the current price of Biohaven Ltd (BHVN)?
The current price of Biohaven Ltd (BHVN) is 10.720.
What is the symbol of Biohaven Ltd?
The ticker symbol of Biohaven Ltd is BHVN.
What is the 52-week high of Biohaven Ltd?
The 52-week high of Biohaven Ltd is 44.280.
What is the 52-week low of Biohaven Ltd?
The 52-week low of Biohaven Ltd is 7.480.
What is the market capitalization of Biohaven Ltd?
The market capitalization of Biohaven Ltd is 1.13B.
What is the net income of Biohaven Ltd?
The net income of Biohaven Ltd is -846.42M.
Is Biohaven Ltd (BHVN) currently rated as Buy, Hold, or Sell?
According to analysts, Biohaven Ltd (BHVN) has an overall rating of Buy, with a price target of 19.563.
What is the Earnings Per Share (EPS TTM) of Biohaven Ltd (BHVN)?
The Earnings Per Share (EPS TTM) of Biohaven Ltd (BHVN) is -7.515.
Related Instruments
+0.41%
+0.94%
+0.51%
+0.34%
-0.17%
+1.42%
+0.75%
+1.80%
+0.38%
+0.66%
+0.08%
+0.82%
+0.81%
+0.08%
+0.23%
-0.05%
-0.19%
0.00%
+1.54%
+0.50%
